Enhertu is a HER2-directed antibody and topoisomerase inhibitor conjugate. Approval of the new indication was based on data from the phase 3 DESTINY-Breast06 trial (ClinicalTrials.gov Identifier: ...

The primary analysis of KATHERINE, a phase 3, open-label trial, showed that the risk of invasive breast cancer or death was 50% lower with adjuvant trastuzumab emtansine (T-DM1) than with ...

In patients with high-risk HER2-positive breast cancer, post-surgery, or adjuvant, treatment with trastuzumab emtansine (T-DM1) reduced the long-term risk of death or invasive disease by 46% and ...

The other 743 women (median age, 49 years; range, 23-80; 71.5% white) received trastuzumab 6 mg/kg via IV every 3 weeks for 14 cycles. Invasive DFS served as the primary endpoint. OS served as a ...

The decision to fund trastuzumab deruxtecan will enable women ... Palivizumab was a monthly injection that helped protect babies and young children from RSV (respiratory syncytial virus), and ...

Metastatic cancer (stage IV) has specific treatment protocols ... In 1998, Herceptin (trastuzumab), the first medication to directly target HER2, was approved by the FDA. Oncologists usually ...

Adjuvant therapy with trastuzumab emtansine has shown improved outcomes. New research findings are summarized in a short video.

Trastuzumab emtansine (T-DM1) demonstrates sustained improvement in invasive disease-free survival and reduced the risk for death in human epidermal growth factor receptor 2 (HER2)-positive breast ...

At seven-years follow up, invasive disease-free survival was 80.8% with adjuvant T-DM1 and 67.1% with adjuvant trastuzumab alone. Overall survival was 89.1% with T-DM1 and 84.4% with trastuzumab ...